Advances in epigenetics and epigenomics for neurodegenerative diseases

Current Neurology and Neuroscience Reports

Volumn 11, Issue 5, 2011, Pages 464-473

  Qureshi, Irfan A ^a   Mehler, Mark F ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Chromatin; DNA methylation; Epigenetics; Epigenomics; Histone modification; Huntington's disease; Neurodegenerative disease; Next generation sequencing; Non coding RNA; Parkinson's disease

Indexed keywords

BISULFITE; DNA METHYLTRANSFERASE; ELONGATOR PROTEIN 3; GENE PRODUCT; HUNTINGTIN; LONG UNTRANSLATED RNA; MICRORNA; RE1 SILENCING TRANSCRIPTION FACTOR; RNA BINDING PROTEIN; TAR DNA BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANALYTIC METHOD; ARTICLE; CHROMATIN; DEGENERATIVE DISEASE; DNA METHYLATION; DNA MICROARRAY; DNA MODIFICATION; EPIGENETIC DYSREGULATION; EPIGENETICS; GENE EXPRESSION; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HISTONE MODIFICATION; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RNA PROCESSING; TRANSCRIPTION REGULATION; ULTRA HIGH THROUGHPUT RNA SEQUENCING;

CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENOMICS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 81055157117     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0210-2     Document Type: Article

References (86)

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921. (Pubitemid 32165345)
2. Gandhi S, Wood NW. Genome-wide association studies: the key to unlocking neurodegeneration? Nat Neurosci. 2010;13:789-94.
3. Mehler MF. Epigenetic principles and mechanisms underlying nervous system functions in health and disease. Prog Neurobiol. 2008;86:305-41.
4. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007;447:433-40. (Pubitemid 46816750)
5. Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19:698-711.
6. Meda F, Folci M, Baccarelli A, Selmi C. The epigenetics of autoimmunity. Cell Mol Immunol. 2011.
7. Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res. 2011;67:175-95.
8. Kurdistani SK. Histone modifications in cancer biology and prognosis. Prog Drug Res. 2011;67:91-106.
9. Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res. 2011;67:1-23.
10. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol. 2010;11:607-20.
11. Qureshi IA, Mehler MF. Impact of nuclear organization and dynamics on epigenetic regulation in the central nervous system: implications for neurological disease states. Ann NY Acad Sci. 2010;1204(Suppl):E20-37.
12. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074-80. (Pubitemid 32758077)
13. Ruthenburg AJ, Li H, Patel DJ, Allis CD. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol. 2007;8:983-94. (Pubitemid 350174643)
14. Kapranov P, St Laurent G, Raz T, et al. The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol. 2010;8:149.
15. Mattick JS, Taft RJ, Faulkner GJ. A global view of genomic information-moving beyond the gene and the master regulator. Trends Genet. 2010;26:21-8.
16. Qureshi IA, Mattick JS, Mehler MF. Long non-coding RNAs in nervous system function and disease. Brain Res. 2010;1338:20-35.
17. Mattick JS, Amaral PP, Dinger ME, et al. RNA regulation of epigenetic processes. Bioessays. 2009;31:51-9.
18. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11:597-610.
19. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155-9.
20. Chuang DM, Leng Y, Marinova Z, et al. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 2009;32:591-601.
21. Lee J, Ryu H. Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker? BMB Rep. 2010;43:649-55.
22. Tohgi H, Utsugisawa K, Nagane Y, et al. The methylation status of cytosines in a tau gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex. Neurosci Lett. 1999;275:89-92. (Pubitemid 29502543)
23. Tohgi H, Utsugisawa K, Nagane Y, et al. Reduction with age in methylcytosine in the promoter region -224 approximately -101 of the amyloid precursor protein gene in autopsy human cortex. Brain Res Mol Brain Res. 1999;70:288-92. (Pubitemid 29317643)
24. West RL, Lee JM, Maroun LE. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci. 1995;6:141-6.
25. Mastroeni D, Grover A, Delvaux E, et al. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging. 2010;31:2025-37.
26. Mastroeni D, McKee A, Grover A, et al. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One. 2009;4:e6617.
27. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS One. 2008;3:e2698.
28. Chen KL, Wang SS, Yang YY, et al. The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. Biochem Biophys Res Commun. 2009;378:57-61.
29. Wu J, Basha MR, Brock B, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci. 2008;28:3-9.
30. Cao X, Sudhof TC. A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115-20. (Pubitemid 32625507)
31. Marambaud P, Wen PH, Dutt A, et al. A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of Ncadherin is inhibited by PS1 FAD mutations. Cell. 2003;114:635-45. (Pubitemid 37159259)
32. Rouaux C, Jokic N, Mbebi C, et al. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003;22:6537-49. (Pubitemid 38009601)
33. Saura CA, Choi SY, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42:23-36. (Pubitemid 38456965)
34. Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14:27-41. (Pubitemid 352039013)
35. Guo JH, Cheng HP, Yu L, Zhao S. Natural antisense transcripts of Alzheimer's disease associated genes. DNA Seq. 2006;17:170-3. (Pubitemid 47215747)
36. FaghihiMA, Modarresi F, Khalil AM, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14:723-30.
37. Buckley NJ, Johnson R, Zuccato C, et al. The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease. Neurobiol Dis. 2010;39:28-39.
38. Seong IS, Woda JM, Song JJ, et al. Huntingtin facilitates polycomb repressive complex 2. Hum Mol Genet. 2010;19:573-583.
39. Shimojo M. Huntingtin regulates RE1-silencing transcription factor/neuron-restrictive silencer factor (REST/NRSF) nuclear trafficking indirectly through a complex with REST/NRSFinteracting LIM domain protein (RILP) and dynactin p150 Glued. J Biol Chem. 2008;283:34880-6.
40. Johnson R, Zuccato C, Belyaev ND, et al. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol Dis. 2008;29:438-45.
41. Packer AN, Xing Y, Harper SQ, et al. The bifunctional microRNA miR-9/miR-9* regulates RESTand CoREST and is downregulated in Huntington's disease. J Neurosci. 2008;28:14341-6.
42. Marti E, Pantano L, Banez-Coronel M, et al. A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res. 2010.
43. Johnson R, Richter N, Jauch R, et al. The Human Accelerated Region 1 noncoding RNA is repressed by REST in Huntington's disease. Physiol Genomics. 2010.
44. Marullo M, Valenza M, Mariotti C, et al. Analysis of the repressor element-1 silencing transcription factor/neuron-restrictive silencer factor occupancy of non-neuronal genes in peripheral lymphocytes from patients with Huntington's disease. Brain Pathol. 2010;20:96-105.
45. Jowaed A, Schmitt I, Kaut O, Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci. 2010;30:6355-9.
46. Matsumoto L, Takuma H, Tamaoka A, et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One. 2010;5:e15522.
47. Junn E, Lee KW, Jeong BS, et al. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA. 2009;106:13052-7.
48. Desplats P, Spencer B, Coffee E, et al. Alpha-synuclein sequesters DNMT1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem. 2011.
49. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006;15:3012-23. (Pubitemid 44530705)
50. Santosh PS, Arora N, Sarma P, et al. Interaction map and selection of microRNA targets in Parkinson's disease-related genes. J Biomed Biotechnol. 2009;2009:363145.
51. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature. 2010;466:637-641.
52. Simpson CL, Lemmens R, Miskiewicz K, et al. Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet. 2009;18:472-81.
53. Okada Y, Yamagata K, Hong K, et al. A role for the elongator complex in zygotic paternal genome demethylation. Nature. 2010;463:554-558.
54. Winkler GS, Kristjuhan A, Erdjument-Bromage H, et al. Elongator is a histone H3 and H4 acetyltransferase important for normal histone acetylation levels in vivo. Proc Natl Acad Sci USA. 2002;99:3517-22. (Pubitemid 34252140)
55. Matsumoto T, Yun CS, Yoshikawa H, Nishida H. Comparative studies of genome-wide maps of nucleosomes between deletion mutants of elp3 and hos2 genes of Saccharomyces cerevisiae. PLoS One. 2011;6:e16372.
56. Han Q, Lu J, Duan J, et al. Gcn5- and Elp3-induced histone H3 acetylation regulates hsp70 gene transcription in yeast. Biochem J. 2008;409:779-88. (Pubitemid 351214204)
57. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet. 2010;19:R46-64.
58. Ling SC, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci USA. 2010; 107:13318-13323.
59. Freibaum BD, Chitta RK, High AA, Taylor JP. Global analysis of TDP-43 interacting proteins reveals strong association with RNA splicing and translation machinery. J Proteome Res. 2010;9:1104-20.
60. Buratti E, De Conti L, Stuani C, et al. Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J. 2010;277:2268-81.
61. Williams AH, Valdez G, Moresi V, et al.: MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009, 326:1549-1554.
62. Birney E, Stamatoyannopoulos JA, Dutta A, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447:799-816. (Pubitemid 46920138)
63. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315-22.
64. Gu H, Smith ZD, Bock C, et al. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc. 2011;6:468-81.
65. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009;27:361-8.
66. Rauch TA, Pfeifer GP. The MIRA method for DNA methylation analysis. Methods Mol Biol. 2009;507:65-75.
67. Suzuki M, Greally JM. DNA methylation profiling using HpaII tiny fragment enrichment by ligation-mediated PCR (HELP). Methods. 2010;52:218-22.
68. Bock C, Tomazou EM, Brinkman AB, et al. Quantitative comparison of genome-wide DNA methylationmapping technologies. Nat Biotechnol. 2010;28:1106-14.
69. Harris RA, Wang T, Coarfa C, et al. Comparison of sequencingbased methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol. 2010;28:1097-105.
70. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40:897-903. (Pubitemid 351913645)
71. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129:823-37 (Pubitemid 46802390)
72. Boyle AP, Davis S, Shulha HP, et al. High-resolution mapping and characterization of open chromatin across the genome. Cell. 2008;132:311-22. (Pubitemid 351172431)
73. Hesselberth JR, Chen X, Zhang Z, et al. Global mapping of protein-DNA interactions in vivo by digital genomic footprinting. Nat Methods. 2009;6:283-9.
74. Auerbach RK, Euskirchen G, Rozowsky J, et al. Mapping accessible chromatin regions using Sono-Seq. Proc Natl Acad Sci USA. 2009;106:14926-31.
75. Giresi PG, Kim J, McDaniell RM, et al. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res. 2007;17:877-85. (Pubitemid 46919722)
76. Schones DE, Cui K, Cuddapah S, et al. Dynamic regulation of nucleosome positioning in the human genome. Cell. 2008;132:887-98. (Pubitemid 351312809)
77. Kaplan N, Moore IK, Fondufe-Mittendorf Y, et al. The DNA-encoded nucleosome organization of a eukaryotic genome. Nature. 2009;458:362-6.
78. Deal RB, Henikoff JG, Henikoff S. Genome-wide kinetics of nucleosome turnover determined by metabolic labeling of histones. Science. 2010;328:1161-1164.
79. BrantonD,DeamerDW, Marziali A, et al. The potential and challenges of nanopore sequencing. Nat Biotechnol. 2008;26:1146-53.
80. Hwang do W, Song IC, Lee DS, Kim S. Smart magnetic fluorescent nanoparticle imaging probes to monitor microRNAs. Small. 2010;6:81-8.
81. Lendvai G, Estrada S, Bergstrom M. Radiolabelled oligonucleotides for imaging of gene expression with PET. Curr Med Chem. 2009;16:4445-61.
82. Chen AK, Rhee WJ, Bao G, Tsourkas A. Delivery of molecular beacons for live-cell imaging and analysis of RNA. Methods Mol Biol. 2011;714:159-74.
83. Liu CH, Kim YR, Ren JQ, et al. Imaging cerebral gene transcripts in live animals. J Neurosci. 2007;27:713-22. (Pubitemid 46143775)
84. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007;8:253-62. (Pubitemid 46439287)
85. Jones PA, Archer TK, Baylin SB, et al. Moving AHEAD with an international human epigenome project. Nature. 2008;454:711-715.
86. Jain S, Heutink P. From single genes to gene networks: high-throughput-high-content screening for neurological disease. Neuron. 2010;68:207-17.